In contrast to αCTLA-4-mediated Treg depletion, which is tumor specific (Simpson et al., 2013), DT depletes Treg cells systemically (Kim et al., 2007) (Figure 5A), promoting general activation of CD4+ and CD8+ T cells in both dLNs and tumors. The gene discussed is CD4; the disease is neoplasm.